Xtant Medical Holdings Files 8-K on Financials

TL;DR

XTNT filed an 8-K on 3/31/26 detailing financial results. Check exhibits for specifics.

AI Summary

Xtant Medical Holdings, Inc. filed an 8-K on March 31, 2026, reporting on its Results of Operations and Financial Condition. The filing includes financial statements and exhibits, with specific data likely detailed within the attached documents.

Why It Matters

This 8-K filing provides crucial updates on Xtant Medical Holdings' financial performance and operational results, which are essential for investors to assess the company's current health and future prospects.

Risk Assessment

Risk Level: medium — 8-K filings can contain significant financial information, and the specific details within this report could impact the company's stock price and investor confidence.

Key Players & Entities

• Xtant Medical Holdings, Inc. (company) — Filer of the 8-K report
• 0001453593 (company) — CIK number for Xtant Medical Holdings, Inc.
• 2026-03-31 (date) — Filing date and period of report

FAQ

Key Financial Figures

• $0.000001 — ch registered Common stock, par value $0.000001 per share XTNT NYSE American LLC

Filing Documents

• form8-k.htm (8-K) — 51KB
• ex99-1.htm (EX-99.1) — 146KB
• form8-k_001.jpg (GRAPHIC) — 3KB
• 0001493152-26-013788.txt ( ) — 385KB
• xtnt-20260331.xsd (EX-101.SCH) — 3KB
• xtnt-20260331_lab.xml (EX-101.LAB) — 33KB
• xtnt-20260331_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 3KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2026 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-34951 20-5313323 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 664 Cruiser Lane Belgrade , Montana 59714 (Address of principal executive offices) (Zip Code) (406) 388-0480 (Registrant's telephone number, including area code) Not Applicable (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.000001 per share XTNT NYSE American LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 2.02 Results of Operations and Financial Condition. On March 31, 2026, Xtant Medical Holdings, Inc. (the "Company") announced its financial results for the three months and year ended December 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 2.02 of this report (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any registration statement or other document filed by the Company under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly provided by specific reference in such a filing. To supplement its consolidated financial statements prepared in accordance with United States generally accepted accounting principles ("GAAP"), the Company uses certain non-GAAP financial measures, such as non-GAAP adjusted EBITDA, which are included in the press release furnished as Exhibit 99.1 to this report. The Company defines non-GAAP adjusted EBITDA as net income (loss) from operations before depreciation and amortization expense; interest expense, net; and tax benefit (expense), and as further adjusted to add back in or exclude, non-cash compensation, divestiture/acquisition-related expenses, gain on divestiture, acquisition-related fair value adjustments, unrealized foreign currency translation gain or loss, and separation-related expenses, in each case as applicable. The Company uses non-GAAP adjusted EBITDA in making operating decisions because it believes this measure provides meaningful supplemental information regarding its core operational performance. Additionally, this measure gives the Company a better understanding of how it should invest in sales and marketing and research and development activities and how it should allocate resources to both ongoing and prospective business initiatives. The Company also uses non-GAAP adjusted EBITDA to help make budgeting and spending decisions, for example, among sales and marketing expenses, general and administrative expenses, and research and development expenses. Additionally, the Company believes its use of non-GAAP adjusted EBITDA facilitates management's internal comparisons to historical operating results by factoring out potential differences caused by charges not related to its regular, ongoing business, including, without limitation, non-cash charges and certain large and unpredictable charges and gains. As described above, the Company excludes the effect of the following items from its non-GAAP adjusted EBITDA for the following reasons: Non-cash compensation . The Company excludes non-cash compensation, which is a non-cash charge related to equity awards granted

View Full Filing

View this 8-K filing on SEC EDGAR